Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study
SPICE
SPICE: Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study
1 other identifier
interventional
30
1 country
1
Brief Summary
Despite increasing recognition of sexual dysfunction and sexual distress as important survivorship issues in oncology, research and clinical attention remain uneven across cancer types. This imbalance is particularly evident in bladder cancer, where sexual health has received limited research and clinical attention. However, existing studies demonstrate substantial sexual dysfunction and reduced intimacy among patients following disease and treatment. The treatment of bladder cancer is a multimodal and multidisciplinary discipline. Low-risk non-muscle-invasive bladder cancer (NMIBC) is treated by transurethral resection of the bladder (TURB) alone, while recurrent intermediate- and high-risk NMIBC undergo a combination of TURB and adjuvant intravesical instillation therapy. For patients with muscle-invasive bladder cancer (MIBC) and specific high-risk NMIBC cases, the first-line treatment option is radical cystectomy with urinary diversion, with or without neoadjuvant chemotherapy. These treatment modalities are known to have a negative impact on sexual function, and studies in both men and women demonstrate profound impairments in sexual function, intimacy, and body image after treatment. Among men, erectile and ejaculatory dysfunction are prevalent for this patient group and frequently associated with diminished sexual satisfaction and body-image concerns. Likewise, women experience loss of sexual desire, orgasmic disorders, dyspareunia, and vaginal dryness following cystectomy. A targeted literature search further identified no contemporary sexology-focused interventional or feasibility trials specifically in bladder cancer (neither MIBC or NMIBC). Existing evidence on the topic is largely descriptive or addresses non-sexological rehabilitation, demonstrating a evidence gap\[1\]. Qualitative research has also explored informational and psychosocial needs among bladder cancer patients, revealing limited communication about sexual health and unmet needs for professional support. Such studies provide valuable insight into patient experiences but have not yet translated this knowledge into the development of structured, sexological interventions. Evidence from other cancer populations demonstrates that counselling and psychoeducational programmes addressing intimacy and sexuality are both feasible and beneficial, suggesting that similar interventions could be adapted for bladder cancer care. To develop a relevant and acceptable intervention, it is essential to understand how patients themselves perceive their sexual health challenges, informational needs, and preferences for professional support regarding sexual health. This project therefore consists of two sequential sub-studies:
- Study 1a (Development phase): A qualitative, exploratory study to develop a sexological intervention with patient and clinician involvement.
- Study 1b (Feasibility phase): A one-armed feasibility trial assessing the implementation and acceptability of the intervention among patients with muscle-invasive bladder cancer (MIBC).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jan 2026
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 10, 2025
CompletedStudy Start
First participant enrolled
January 1, 2026
CompletedFirst Posted
Study publicly available on registry
January 14, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 31, 2028
January 14, 2026
October 1, 2025
1.7 years
December 10, 2025
January 5, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (8)
Study 1a: Patient-perceived sexual health challenges identified through semi-structured qualitative interviews
Patient perceptions of sexual health challenges will be explored through semi-structured individual interviews. Interviews will be audio-recorded, transcribed verbatim, and analyzed using thematic analysis. Results will be reported as descriptive themes representing common challenges across participants.
1 year
Study 1a: Patient informational needs regarding sexual health identified through semi-structured qualitative interviews
Patient informational needs related to sexual health will be assessed through semi-structured individual interviews. Interview transcripts will be analyzed using thematic analysis, and results will be reported as themes describing shared informational needs.
1 year
Study 1a: Patient preferences for professional sexual health support identified through semi-structured qualitative interviews
Patient preferences for professional sexual health support will be explored using semi-structured individual interviews. Data will be analyzed using thematic analysis, and findings will be reported as themes describing preferred type, timing, and format of support.
1 year
Study 1b: Recruitment rate
Recruitment rate will be defined as the number of participants enrolled divided by the number of eligible participants approached during the recruitment period.
2 years
Study 1b: Retention rate
Retention rate will be defined as the proportion of enrolled participants who complete all required study assessments.
2 years
Study 1b: Adherence to study protocol
Protocol adherence will be assessed as the proportion of participants who complete the intervention according to the predefined study procedures.
2 years
Study 1b: Response rate to patient-reported outcome measures
Response rate will be defined as the proportion of completed patient-reported outcome questionnaires out of the total number of questionnaires distributed.
2 years
Study 1b: Data completeness of patient-reported outcome measures
Data completeness will be assessed as the proportion of fully completed items across all patient-reported outcome measures.
2 years
Secondary Outcomes (3)
Study 1b: Sexual function assessed by the Female Sexual Function Index (FSFI)
2 years
Study 1b: Sexual distress assessed by the Female Sexual Distress Scale-Revised (FSDS-R)
2 years
Study 1b: Wellbeing assessed by the WHO-5 Well-Being Index
2 years
Study Arms (1)
Intervention arm (study 1b)
EXPERIMENTALInterventions
Results from Study 1a will inform the development and refinement of the intervention to be tested in the feasibility phase (Study 1b).
Eligibility Criteria
You may qualify if:
- The participant has one of the following diagnoses and received initial treatment approximately 12 months ago:
- Non-muscle-invasive bladder cancer treated with transurethral resection of the bladder (TUR-B)
- Non-muscle-invasive bladder cancer treated with TUR-B and subsequent intravesical instillation therapy with chemotherapy or immunotherapy
- Muscle-invasive bladder cancer treated with cystectomy (removal of the bladder)
- The participant has experienced changes and/or difficulties in sexual function related to the cancer diagnosis and/or its treatment
- The participant speaks and understands Danish
- The participant is aged 18 years or older
- The participant has read and understood the oral and written study information
- The participant has provided written informed consent
You may not qualify if:
- The participant has a history of other cancers located in the pelvic region, including rectal cancer, sarcomas, uterine cancer, cervical cancer, ovarian cancer, prostate cancer, or penile cancer
- The participant has a history of breast cancer
- The participant is diagnosed with Muscle-invasive bladder cancer treated with cystectomy (removal of the bladder)
- The participant speaks and understands Danish
- The participant is aged 18 years or older
- The participant has read and understood the oral and written study information
- The participant has provided written informed consent
- The participant has a history of other cancers located in the pelvic region, including rectal cancer, sarcomas, uterine cancer, cervical cancer, ovarian cancer, prostate cancer, or penile cancer
- The participant has a history of breast cancer
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Urology, Aarhus University Hospital
Aarhus, 8200, Denmark
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- SEQUENTIAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 10, 2025
First Posted
January 14, 2026
Study Start
January 1, 2026
Primary Completion (Estimated)
August 31, 2027
Study Completion (Estimated)
August 31, 2028
Last Updated
January 14, 2026
Record last verified: 2025-10